COGT

Cogent Biosciences Inc
15.17
-0.33 (-2.13%)
Upgrade to Real-Time
Afterhours (Closed)
15.17
Volume 528,579
Bid Price 14.85
Ask Price 16.00
News (1)
Day High 15.68

Low
3.79

52 Week Range

High
18.07

Day Low 14.89
Company Name Stock Ticker Symbol Market Type
Cogent Biosciences Inc COGT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.33 -2.13% 15.17 20:00:00
Open Price Low Price High Price Close Price Prev Close
15.31 14.89 15.68 15.17 15.50
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,448 528,579 $ 15.16 $ 8,012,654 - 3.79 - 18.07
Last Trade Time Type Quantity Stock Price Currency
19:04:52 90 $ 14.97 USD

Period:

Draw Mode:

Cogent Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.06B 69.89M 68.31M $ - $ - -1.87 -6.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 4.31k 7.30%

more financials information »

Cogent Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical COGT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.7915.6814.1514.92548,4930.382.57%
1 Month12.0215.6811.5813.41699,9833.1526.21%
3 Months12.6815.6810.46512.11782,8772.4919.64%
6 Months10.5218.0710.46513.74909,0734.6544.2%
1 Year7.0118.073.7910.221,263,4808.16116.41%
3 Years2.2018.072.209.76736,55112.97589.55%
5 Years3.6018.072.209.36724,45511.57321.39%

Cogent Biosciences Description

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.